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ABSTRACT
We report our experience of very late stent thrombosis (VLST) in a young male patient who underwent implantation of two 
paclitaxel-eluting stents (PES) six years ago. The patient was compliant with standard dual antiplatelet therapy, but he pre-
sented with acute myocardial infarction which was associated with VLST. Intravascular ultrasound showed neointimal rup-
ture with thrombus within the PES implanted in the right coronary artery. The lesion was successfully treated with balloon 
angioplasty without complications, however he was found to be hyporesponsive to clopidogrel when tested for adenosine 
diphosphate-induced platelet aggregation. The patient was discharged after uneventful recovery with triple anti-platelet thera-
py using aspirin, clopidogrel and cilostazol. To the best of our knowledge, a time interval of 2,223 days is the longest reported 
time interval between PES deployment and VLST occurrence. VLST may indeed occur in clinically stable patients, as multi-
ple factors can influence the pathological mechanisms of VLST. (Korean Circ J 2011;41:754-758)
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Introduction
Drug-eluting stents (DES) provide clinical benefit by re-
tarding smooth muscle cell replication and extracellular ma-
trix production leading to restenosis, but may delay endothe-
lial healing and heighten the risk of subsequent thrombosis.
1)2) 
Although similar rates of early and late stent thrombosis were 
observed between DES and bare metal stent (BMS), a higher 
rate of very late stent thrombosis (VLST) beyond 12 months 
was reported with DES.
3)
We present a case of very late paclitaxel-eluting stent (PES) 
thrombosis which occurred six years after successful implan-
tation of DES. 
Case
A 39-year-old male underwent coronary stent implantation 
for stable angina pectoris in September 2004. The only risk 
factor included was dyslipidemia. The patient had a throm-
botic nearly total occlusion of the middle right coronary ar-
tery (RCA) {Type C, 99%, thrombolysis in myocardial infarc-
tion (TIMI) flow I} (Fig. 1A) and a critical stenosis in the mid-
dle left anterior descending artery (LAD) (Type B2, 90%, TI-
MI flow III) (Fig. 1B). After intracoronary administration of 
a glycoprotein IIb/IIIa inhibitor (ReoPro
®), percutaneous tr-
ansluminal coronary angioplasty using a 3.5 mm balloon was 
performed, and a 3.5×32 mm PES (Taxus Express II stent, 
Boston Scientific Corporation Natick, MA, USA) was deployed 
in the RCA (Fig. 1C) and a 3.0×20 mm PES in the LAD (Fig. 
1D). He was compliant with his medications which were as 
follows: aspirin 100 mg, clopidogrel 75 mg, cilostazol 200 
mg, carvedilol 6.25 mg, losartan 25 mg, ezetimibe 10 mg, 
simvastatin 20 mg and isosorbide dinitrate 80 mg. In Febru-
ary 2005, follow-up coronary angiography was performed 
because of mild chest pain, and it showed no in-stent resteno-
sis in both the coronary arteries (Fig. 2). Cilostazol was stopped 
6 months after DES implantation. He was continued on medi-
cation with dual antiplatelet agents for 5 years. During follow-Won Ju Kee, et al.   755
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Fig. 2. Coronary angiography was performed 5 months later. No in-stent restenosis in the left anterior descending artery (A) and right coro-
nary artery (B) stents were observed on follow-up coronary angiogram.
up, two-dimensional echocardiogram showed no regional 
wall motion abnormality with an ejection fraction of 69.4%, 
and the treadmill test was negative at 12.8 METS, just 3 months 
prior to re-admission. 
The patient presented to the emergency room with sudden 
onset, left-sided chest pain without radiation in October 2010. 
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Fig. 1. Initial coronary angiography in September 2004. A: thrombotic nearly total occlusion of the middle right coronary artery (RCA) (Type 
C, 99%, TIMI flow I). B: critical stenosis in the middle left anterior descending artery (LAD) (Type B2, 90%, TIMI flow III). C: 3.5×32 mm pa-
clitaxel-eluting stent (Taxus Express II stent) was deployed in the RCA. D: 3.0×20 mm paclitaxel-eluting stent in the LAD. The final coronary 
angiography showed good distal flow without residual stenosis in both the coronary arteries. TIMI: Thrombolysis in Myocardial Infarction.756   Very Late Stent Thrombosis due to Neointima Rupture
A 12-lead ECG showed ST-segment elevation in the lead II, 
III, aVF and Mobitz type II second degree atrioventricular 
block (Fig. 3). He had a normal complete blood count, with 
white blood cell count of 5,900/mm
3, hemoglobin of 13.8 g/
dL, hematocrit of 41.1%, and platelet count of 199,000/mm
3. 
The results of electrolyte panel, kidney function studies, liver 
Fig. 3. A 12-lead electrocardiography showed ST-segment elevation in the lead II, III, aVF and Mobitz type II second degree atrioventricular 
block.
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Fig. 4. A: right coronary angiogram showed very late stent thrombosis in the right coronary artery (RCA) stent. B: intravascular ultrasound (IVUS) 
showed neointimal rupture with thrombus within the RCA stent. C: coronary angiography after plain old balloon angioplasty. The final coro-
nary angiogram showed good distal flow in the RCA. D: IVUS showed markedly decreased residual stenosis in the RCA. 
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function studies, and lipid panel were all within normal lim-
its except for the low-density lipoprotein cholesterol of 86 
mg/dL. Cardiac enzymes were initially normal. 
The patient underwent cardiac angiogram and it revealed 
stent thrombosis in the RCA (99%, I, 0) (Fig. 4A) and mild 
type II in-stent restenosis in the LAD (40%, III, 0) (Fig. 5). In-
travascular ultrasound (IVUS) showed neointimal rupture 
with thrombus in the RCA stent (Fig. 4B). Plain old balloon 
angioplasty with a 3.5×15 mm balloon was performed in 
the RCA and the final coronary angiogram and IVUS showed 
good distal flow and markedly decreased residual stenosis in 
the RCA (Fig. 4C and D). He was found to be hyporesponsive 
to clopidogrel when tested for adenosine diphosphate-induc-
ed platelet aggregation utilizing the Verify Now P2Y12 point-
of-care assay (301/14 P2Y12 reaction unit/%). He was disch-
arged after uneventful recovery with triple anti-platelet ther-
apy using aspirin 100 mg, clopidogrel 75 mg, cilostazol 200 
mg daily. The patient has been followed-up at the outpatient 
department without any further symptoms.
 
Discussion
 
The primary concern regarding long-term safety of DES is 
stent thrombosis, a potentially fatal adverse event that often 
leads to myocardial infarction or death. While randomized stu-
dies have not found an increased rate of late stent thrombosis 
in DES compared with BMS, reports of VLST in DES patients 
continue to increase in the literature with increasing use of 
these stents.
4-8) VLST after the placement of a PES occurs in 
the range of 0.46-0.63%.
9)10)
Although the mechanisms of VLST have not been com-
pletely understood, it is presumed that delayed endothelializ-
ation and chronic inflammation are implicated in the patho-
physiology of VLST.
11) Neointimal rupture is another possible 
mechanism underlying VLST development. Neointimal stent 
coverage has an effect on plaque stabilization due to the com-
plete sealing of the stent by the neointima underlying the 
ruptured plaque. The exact mechanism of neointimal rup-
ture remains unclear. Because the stent itself has thromboge-
nic potential, exposure of the stent through the ruptured neo-
intima or due to inadequate neointima formation would 
increase the risk of thrombosis.
12)13)
In the clinical setting, premature antiplatelet therapy dis-
continuation, renal failure, bifurcation lesions, diabetes and 
decreased left ventricular ejection fraction are the risk factors 
for stent thrombosis.
14) Furthermore, non-responsiveness to 
clopidogrel is associated with higher risk of cardiovascular 
events, including cardiac death and stent thrombosis. The pre-
valence of clopidogrel resistance in the patient population was 
reported in the range of 5 to 44%.
15)16) In this case, considering 
the fact that stent thrombosis occurred while he was on dual 
antiplatelet therapy and finally the patient was found to be 
hyporesponsive to clopidogrel, further investigations are ne-
eded to screen the patients at risk for stent thrombosis and to 
determine the adequate antiplatelet regimen beyond the st-
andard dual antiplatelet therapy after DES implantation.
To the best of our knowledge, a time interval of 2,223 days 
is the longest reported time interval between PES deployment 
and VLST occurrence. We can conclude that VLST may inde-
ed occur in clinically stable patients, as multiple factors can 
influence the pathological mechanisms of VLST. This case 
highlights the need for further long-term studies on VLST 
occurrence including the pathophysiology and predisposing 
factors of VLST, in patients treated with DES.
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